Melinta Therapeutics

Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey.[1]

Melinta Therapeutics
IndustryPharmaceutical
Founded2000
HeadquartersParsippany, NJ
Area served
Worldwide
ProductsBroad-spectrum antibiotics
Websitemelinta.com

In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics.[2] It was renamed Melinta Therapeutics in 2013.[3]

One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006,[2] was approved by the FDA in 2017.[4]

As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.[3]

Melinta shredded off its discovery research team in late 2018.[5] It also moved its headquarters from New Haven to Morristown, New Jersey in early 2019.

On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.[6]

On April 2020, it was transferred to affiliates of its creditor Deerfield Management.[5]

References
  1. Carroll, John (2011). "Rib-X Pharmaceuticals - 2011 Fierce 15". FierceBiotech.
  2. Cartwright, Heather (12 July 2011). "Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi". PharmaDeals Review. No. 7. doi:10.3833/pdr.v2011i7.1494 (inactive 1 August 2023). Archived from the original on 25 April 2012.{{cite news}}: CS1 maint: DOI inactive as of August 2023 (link)
  3. Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.
  4. Osborne, Randy (20 June 2017). "Melinta's I.V., oral delafloxacin wins FDA nod in skin infections". BioWorld. Archived from the original on 3 August 2019. Retrieved 10 July 2017.
  5. Missakian, Natalie (April 23, 2020). "Antibiotics maker Melinta emerges from bankruptcy under new ownership". Hartford Business. Retrieved 23 November 2022.
  6. "Antibiotics maker Melinta files for Chapter 11 bankruptcy". Reuters. 2019-12-27. Retrieved 2019-12-29.

40.80164°N 74.45860°W / 40.80164; -74.45860

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.